SCHEMBL6948170

SCHEMBL6948170

COc1cc2c(cc1OC)CCN[CH]2

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOA P21397 6/20 0.47
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 3/20 0.47
GLA P06280 2/20 0.47
TSHR P16473 1/20 0.46
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
HTR2A P28223 4/20 0.44
HTR2C P28335 4/20 0.44
HTR2B P41595 4/20 0.44
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 1/20 0.41
CHRNA7 P36544 1/20 0.38
MAOB P27338 1/20 0.38
SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10650554 0.81 MAOA (0.45) MAOAALDH1A1KDM4EGLATSHR
SCHEMBL29561779 0.81 MAOA (0.45) MAOAALDH1A1KDM4EGLATSHR
SCHEMBL27975495 0.73 ATM (0.38) ALDH1A1KDM4ECYP3A4MAPTKMT2A
SCHEMBL3162737 0.73 HTR2A (0.74) MAOAKDM4ETSHRCYP3A4MAPT
Hydrochloric Acid SCHEMBL4247274 0.71 HTR2A (0.71) MAOAKDM4ETSHRCYP3A4MAPT
SCHEMBL4434939 0.69 MAOA (0.52) MAOAALDH1A1KDM4EGLATSHR
SCHEMBL29924708 0.69 MAPT (0.68) MAOAALDH1A1KDM4EGLATSHR
SCHEMBL14481557 0.69 MAPT (0.68) MAOAALDH1A1KDM4EGLATSHR
SCHEMBL2594537 0.69 MAPT (0.68) MAOAALDH1A1KDM4EGLATSHR
SCHEMBL329913 0.68 HTR2A (0.61) MAOATSHRCYP3A4MAPTHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204002-B1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS INTERNATIONAL SOC FOR DRUG DEVELOPMENT S R L (IT) 2021-05-19 EP claimed
US-10744127-B2 MDR-reversing 8-hydroxy-quinoline derivatives MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) 2020-08-18 US claimed
CN-109761945-B naringenin-O-alkylamine compound, preparation method and application 南阳师范学院 2020-07-31 CN claimed
CN-109651321-B apigenin-O-alkylamine compound, preparation method and application 南阳师范学院 2020-06-26 CN claimed
US-20190151306-A1 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) 2019-05-23 US claimed
EP-3440070-A2 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES Magyar Tudományos Akadémia Természettudományi Kutatóközpont (HU) 2019-02-13 EP claimed
WO-2017175018-A2 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) 2017-10-12 WO claimed
EP-3204002-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS International Society for Drug Development S.r.l. (IT) 2017-08-16 EP claimed
WO-2016055454-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) 2016-04-14 WO claimed
US-20030073641-A1 Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2003-04-17 US claimed
US-5883107-A ANTITHROMBOTIC AGENTS CORVAS INTERNATIONAL, INC. (US) 1999-03-16 US claimed
CN-1202888-A Isoquinoline derivatives and isoquinoline combinatorial libraries TORREY PINES INST (US) 1998-12-23 CN claimed
EP-0877737-A1 NOVEL N-(ARYLSULPHONYL)AMINO ACID DERIVATIVES HAVING BRADYKININ RECEPTOR AFFINITY SANOFI (FR) 1998-11-18 EP claimed
CN-1171116-A N-substituted glycine derivatives as factor Xa inhibitors CORVAS INT INC (US) 1998-01-21 CN claimed
US-5696231-A ANTICOAGULANTS; CARDIOVASCULAR DISORDERS CORVAS INTERNATIONAL, INC. (US) 1997-12-09 US claimed
WO-1997025315-A1 NOVEL N-(ARYLSULPHONYL)AMINO ACID DERIVATIVES HAVING BRADYKININ RECEPTOR AFFINITY SANOFI (FR) 1997-07-17 WO claimed
US-5618814-A Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds DR. KARL THOMAE GMBH (DE) 1997-04-08 US claimed
WO-1996019493-A1 N-SUBSTITUTED GLYCINE DERIVATIVES AS INHIBITORS OF FACTOR Xa CORVAS INTERNATIONAL, INC. (US) 1996-06-27 WO claimed
US-4914092-A ANTIULCER AGENTS SYNTHELABO (FR) 1990-04-03 US claimed
US-4487774-A Isochromans THE UPJOHN COMPANY (US) 1984-12-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151306-A1 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES ABCC1, ABCB1, ABCC8 MAOA 4466/4885ALDH1A1 949/4885KDM4E 1370/4885
US-10744127-B2 MDR-reversing 8-hydroxy-quinoline derivatives ABCC1, ABCB1, ABCC8 MAOA 4466/4885ALDH1A1 949/4885KDM4E 1370/4885
US-20030073641-A1 Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them CYP2C9, ADRM1, ADRA1D MAOA 375/4885ALDH1A1 503/4885KDM4E 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.